These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34224330)

  • 21. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model.
    Yuan L; Zhu H; Wu K; Zhou M; Ma J; Chen R; Tang Q; Cheng T; Guan Y; Xia N
    Signal Transduct Target Ther; 2022 Feb; 7(1):47. PubMed ID: 35165265
    [No Abstract]   [Full Text] [Related]  

  • 23. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
    Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
    Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs.
    Gupta A; Gupta GS
    Mol Cell Biochem; 2021 Aug; 476(8):2917-2942. PubMed ID: 33745077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
    Campos DMO; Fulco UL; de Oliveira CBS; Oliveira JIN
    J Evid Based Med; 2020 Nov; 13(4):255-260. PubMed ID: 33058394
    [No Abstract]   [Full Text] [Related]  

  • 26. Alopecia areata in a patient with SARS-Cov-2 infection.
    Sgubbi P; Savoia F; Calderoni O; Longo R; Stinchi C; Tabanelli M
    Dermatol Ther; 2020 Nov; 33(6):e14295. PubMed ID: 32909635
    [No Abstract]   [Full Text] [Related]  

  • 27. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 therapy: What weapons do we bring into battle?
    de Almeida SMV; Santos Soares JC; Dos Santos KL; Alves JEF; Ribeiro AG; Jacob ÍTT; da Silva Ferreira CJ; Dos Santos JC; de Oliveira JF; de Carvalho Junior LB; de Lima MDCA
    Bioorg Med Chem; 2020 Dec; 28(23):115757. PubMed ID: 32992245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
    Yang C; Xiao SY
    Biomed Pharmacother; 2021 Mar; 135():111233. PubMed ID: 33433350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hundreds of COVID trials could provide a deluge of new drugs.
    Ledford H
    Nature; 2022 Mar; 603(7899):25-27. PubMed ID: 35233098
    [No Abstract]   [Full Text] [Related]  

  • 33. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
    Haggag YA; El-Ashmawy NE; Okasha KM
    Med Hypotheses; 2020 Nov; 144():109957. PubMed ID: 32531538
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Brown RE; Tahseen D
    Ann Clin Lab Sci; 2020 Nov; 50(6):837-841. PubMed ID: 33334802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
    Cheon SY; Koo BN
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
    Suganya S; Divya S; Parani M
    Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 38. Proposed use of thalidomide for the cytokine storm of COVID-19.
    Goihman-Yahr M
    Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
    [No Abstract]   [Full Text] [Related]  

  • 39. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis.
    Du SQ; Yuan W
    J Med Virol; 2020 Sep; 92(9):1615-1628. PubMed ID: 32356908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.